Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-Nitrosation in human hepatocarcinoma cells

Anticancer Res. 2010 Feb;30(2):415-21.

Abstract

Background/aim: S-Nitrosoglutathione reductase (GSNOR) and thioredoxin enzyme systems participate in cellular defence against nitrosative stress. Pharmacological interventions against these enzyme systems might represent valuable strategies to impair S-nitrosothiol (SNO) homeostasis in tumour cells.

Materials and methods: Human HepG2 cells were pre-treated with mithramycin A or auranofin and exposed to S-nitroso-L-cysteine. GSNOR mRNA levels were analyzed by quantitative real-time reverse transcriptase-polymerase chain reaction and S-nitrosated proteins were detected and purified using the biotin-switch approach. Proteins were identified using electrospray ionization tandem mass spectrometry.

Results: Mithramycin interfered with GSNOR induction resulting in an increased cellular sensitivity to protein S-nitrosation. Moreover, the thioredoxin reductase inhibitor auranofin also increased cellular susceptibility to S-nitrosoprotein formation. The impairment of these two cellular defense systems against nitrosative stress resulted in different sets of S-nitrosated proteins, as revealed by the proteomics approach.

Conclusion: Our results suggest that pharmacological intervention with mithramycin or auranofin may constitute promising tools for altering SNO homeostasis in tumour cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antirheumatic Agents / pharmacology
  • Auranofin / pharmacology*
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology
  • Humans
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Nitrosation
  • Plicamycin / analogs & derivatives*
  • Plicamycin / pharmacology
  • Proteins / metabolism*
  • Proteomics
  • S-Nitrosoglutathione / metabolism*
  • Spectrometry, Mass, Electrospray Ionization
  • Thioredoxin-Disulfide Reductase / antagonists & inhibitors*
  • Thioredoxin-Disulfide Reductase / metabolism*
  • Tumor Cells, Cultured

Substances

  • Antirheumatic Agents
  • Proteins
  • Auranofin
  • S-Nitrosoglutathione
  • mithramycin A
  • Thioredoxin-Disulfide Reductase
  • Plicamycin